Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
The Boehringer Ingelheim group of companies' objectives and beliefs can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision.
Research & Development
Our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need.
How We Discover
From initial discovery to a marketable medicine is a long, challenging road. It takes about 12 - 15 years from discovery to the approved medication and requires an investment of about US $1 billion.
Working at Boehringer Ingelheim – Being part of a global family
As a research-driven pharmaceutical company Boehringer Ingelheim strives to improve health of people and animals everywhere in the world.
28 Sep 2016 at 14:00
European Society for Medical Oncology (ESMO) 2016
ESMO • 07 Oct 2016 09:00 AM • Copenhagen • Denmark
New Member of the Board of Managing Directors of Boehringer Ingelheim/ Responsible for Corporate Board Division Finance
@BOEHRINGER 05 Sep 2016 at 14:14
03 Aug 2016 at 10:00
Boehringer Ingelheim: Growth in all core businesses
Acute Ischaemic Stroke
Valeria Caso introduces the Angels Initiative
We want to improve acute stroke care by building a community of 1,500 stroke centres and stroke ready hospitals by May 2019
Making More Health
MMH Talk of Francesca Fidelli
Partnerships are important in creating innovation. Read more about Dr Paola Casarosa and her work on developing therapeutic alliances and strategic partnerships.